Ignite Creation Date:
2025-12-24 @ 6:36 PM
Ignite Modification Date:
2026-02-22 @ 9:54 AM
Study NCT ID:
NCT02953457
Status:
COMPLETED
Last Update Posted:
2024-11-19
First Post:
2016-11-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Sponsor:
Roswell Park Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06-29
Start Date Type:
ACTUAL
Primary Completion Date:
2021-09-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-08-15
Completion Date Type:
ACTUAL
First Submit Date:
2016-11-01
First Submit QC Date:
None
Study First Post Date:
2016-11-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-07-05
Results First Submit QC Date:
None
Results First Post Date:
2022-10-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-31
Last Update Post Date:
2024-11-19
Last Update Post Date Type:
ACTUAL